CPIX   $3.14  2.28% Market Closed

Cumberland Pharmaceuticals Inc.
Last Events:

2023-08-09 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-04 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: entrance to the overbought zone.

2023-08-03 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it crossed the signal line from the top and falls. These factors mean that the market confirms the tendency to fall. Last signal: main and signal line crossing.

2023-07-30 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.


Current temperature: 6.22
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 2.92
High with % probability:
Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch None None None
ma20 None ActivelyBuy ActivelyBuy
ma50 None None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternMarch 30, 2026 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US2307701092
ceo Mr. A. J. Kazimi MBA
Website https://www.cumberlandpharma.com
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.